Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from vTv Therapeutics ( (VTVT) ) is now available.
vTv Therapeutics has updated their slide presentation to highlight their progress in developing cadisegliatin, a novel oral liver-selective glucokinase activator for Type 1 Diabetes. This development, still undergoing clinical trials and regulatory processes, aims to address the high unmet need for more effective glycemic control solutions, potentially providing investors and stakeholders with significant market opportunities.
More about vTv Therapeutics
vTv Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of oral drugs for chronic diseases. Their primary market involves treatments for diabetes, specifically targeting Type 1 Diabetes with their advanced cadisegliatin program.
YTD Price Performance: 1.68%
Average Trading Volume: 30,901
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $44.02M
For an in-depth examination of VTVT stock, go to TipRanks’ Stock Analysis page.
